A review of life science current events reported by MedCity News this week:
Exclusive interview with Omar Ishrak: Medtronic will be even more global. What will Medtronic (NYSE:MDT) look like under Omar Ishrak? Medtronic will be less exclusively a therapy-oriented company as it looks to find revenue by leveraging other resources such as technology and health IT. It will be more international. And it will be involved in developing the infrastructure – in other words training doctors and providing awareness – as it seeks to provide more access to healthcare overseas.
GSK’s new drug marketing model: Pharma reps as educators, not sellers. …GSK is aiming to remove financial incentives from the equation. Pharma reps still receive a mix of salary and bonus. But GSK replaced individual sales targets with new targets measuring the overall performance of the sales team and feedback from customers.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A reporter’s take on Medtronic CEO Omar Ishrak. Dressed informally without a tie or jacket, Ishrak is comfortable in his own skin. Despite running a multibillion-dollar company, he did not have any airs. He didn’t mind when I ordered him to switch seats because I wanted a perfect video and not one where his face appeared too dark because of the light. And despite the worry of his corporate communications chief, Ishrak was a natural on camera.
India’s medical device industry urges the country to prepare for medtech. India’s medical device industry itself already knows the opportunity that awaits. And leaders there are urging the country to streamline its health system to accommodate medical technology by focusing on solutions for three areas that could hinder the growth of the industry.
Health IT: Is the U.S. in the middle of a bubble? There are several pieces of evidence and anecdotal trends that suggest the possibility of a health IT bubble forming — either now or in the coming years — and that’s something that at the very least should be on investors’ minds as they review dealflow.
